NEW YORK (GenomeWeb) – Qiagen said today that its Artus CMV QS-RGQ molecular diagnostic kit for use on the QiaSymphony platform has received premarket approval from the US Food and Drug Administration.

The real-time PCR assay is designed to be used with human plasma samples, and is intended to aid in the management of solid organ transplant patients who are undergoing anti-cytomegalovirus therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.